-
Mashup Score: 0PSMA-Targeted Radioligand Therapies for mCRPC Show Efficacy, Safety, QoL Benefits - Oncology Nurse Advisor - 13 day(s) ago
Investigators performed an in-depth analysis of radioligand therapy in patients with metastatic prostate cancer, particularly in the castrate-resistant setting (mCRPC).
Source: www.oncologynurseadvisor.comCategories: General Medicine NewsTweet
-
Mashup Score: 4
Alicia Morgans, MD, MPH, discusses findings from a QOL analysis of the ARANOTE trial, which evaluated darolutamide plus ADT in patients with mHSPC.
Source: www.onclive.comCategories: General Medicine NewsTweet-
Darolutamide/ADT Combo Delays Pain Progression and Enhances QOL in mHSPC @CaPsurvivorship @DanaFarberNews #ProstateCancer #PCSM https://t.co/huQZ1FVjMN
-
-
Mashup Score: 3
Rana R. McKay, MD, discusses data from the COMRADE trial, which showed that olaparib plus radium-223 improved rPFS in men with mCRPC with bone metastases.
Source: www.onclive.comCategories: General Medicine NewsTweet-
Olaparib Plus Radium-223 Doubles rPFS vs Radium-223 Alone in mCRPC @DrRanaMcKay #ProstateCancer #PCSM https://t.co/iJOGxrmuF1
-
-
Mashup Score: 0
Patients with prostate cancer may have a lower risk of recurrence if they take multivitamin supplements after diagnosis, new data suggest.
Source: www.cancertherapyadvisor.comCategories: General Medicine NewsTweet-
Patients with #prostatecancer may have a lower risk of recurrence if they take multivitamin supplements after diagnosis. Published in @EurUrolOncol. https://t.co/dS1nwc7at3 #pcsm
-
-
Mashup Score: 5
Marc R. Matrana, MD, discusses the evolving frontline treatment landscape for advanced metastatic prostate cancer.
Source: www.onclive.comCategories: General Medicine NewsTweet-
Marc R. Matrana, MD, of @OchsnerHealth discussed the clinical implications of the phase 3 TALAPRO-2 trial, which evaluated talazoparib/enzalutamide in the first-line treatment of patients with mCRPC. #ProstateCancer #pcsm Read more: https://t.co/9ptRI1hFkh https://t.co/OjUQYgptxz
-
-
Mashup Score: 4Targeted Therapies Both Refine and Raise Questions About CRPC Treatment Decision-Making - 2 month(s) ago
Evan Y. Yu, MD, discusses PARP inhibitor treatment selection and sequencing for patients with metastatic castration-resistant prostate cancer.
Source: www.onclive.comCategories: General Medicine NewsTweet-
Targeted Therapies Both Refine and Raise Questions About CRPC Treatment Decision-Making @fredhutch #ProstateCancer #pcsm https://t.co/zer1kkca4j
-
-
Mashup Score: 3
Marc R. Matrana, MD, discusses the evolving frontline treatment landscape for advanced metastatic prostate cancer.
Source: www.onclive.comCategories: General Medicine NewsTweet-
Talazoparib/Enzalutamide Combo, Radioligand Therapy Expand Options in mCRPC @OchsnerHealth #ProstateCancer #PCSM https://t.co/CRDpWK58NJ
-
-
Mashup Score: 3Targeted Therapies Both Refine and Raise Questions About CRPC Treatment Decision-Making - 2 month(s) ago
Evan Y. Yu, MD, discusses PARP inhibitor treatment selection and sequencing for patients with metastatic castration-resistant prostate cancer.
Source: www.onclive.comCategories: General Medicine NewsTweet-
Targeted Therapies Both Refine and Raise Questions About CRPC Treatment Decision-Making @fredhutch #ProstateCancer #pcsm https://t.co/zer1kkca4j
-
-
Mashup Score: 2Darolutamide Plus ADT Provides Clear Clinical Benefits With Acceptable Tolerability in mHSPC - 2 month(s) ago
ARANOTE data underscore that combining darolutamide with ADT benefits patients with mHSPC irrespective of whether they also receive docetaxel.
Source: www.onclive.comCategories: General Medicine NewsTweet-
The median radiological PFS in patients with metastatic hormone-sensitive #ProstateCancer in the darolutamide/ADT and placebo/ADT arms was not reached vs 25.0 months, respectively. #PCSM Read here for more data: https://t.co/p6swRZlJK5 https://t.co/frRWyKMGIQ
-
-
Mashup Score: 0New Insight into Genetic Drivers of Prostate Cancer - 2 month(s) ago
Study results underscore the importance of including multi-ancestry cohorts in prostate cancer research.
Source: www.renalandurologynews.comCategories: General Medicine News, UrologyTweet-
A recent multinational study has identified genetic clues explaining why some prostate cancers remain slow-growing while others become life-threatening. Read our latest feature: https://t.co/NJnQ1O2tB9 #prostatecancer #pcsm
-
PSMA-targeted radioligand therapies for metastatic castration-resistant #prostatecancer decrease PSA levels and improve QoL with infrequent severe toxic events. From @renalandurology. https://t.co/vGJ1O4Jn0z #pcsm